Buy or sell Freenome stock pre IPO via an EquityZen fund
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
These South Bay and Peninsula cities are raking in venture capital
TechCrunch - Jul, 8 2017